These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 2291563)
1. New orally effective iron chelators. Animal studies. Hershko C; Link G; Pinson A; Avramovici-Grisaru S; Sarel S; Peter HH; Hider RC; Grady RW Ann N Y Acad Sci; 1990; 612():351-60. PubMed ID: 2291563 [No Abstract] [Full Text] [Related]
2. The effect of 2,4-dihydroxypyridine-N-oxide, a new orally active iron chelator, on iron excretion in mice. Kontoghiorghes GJ Clin Chim Acta; 1987 Mar; 163(2):137-41. PubMed ID: 3568416 [TBL] [Abstract][Full Text] [Related]
3. Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation. Chaston TB; Watts RN; Yuan J; Richardson DR Clin Cancer Res; 2004 Nov; 10(21):7365-74. PubMed ID: 15534113 [TBL] [Abstract][Full Text] [Related]
4. An animal model of iron overload and its application to study hepatic ferritin iron mobilization by chelators. Longueville A; Crichton RR Biochem Pharmacol; 1986 Nov; 35(21):3669-78. PubMed ID: 3778498 [TBL] [Abstract][Full Text] [Related]
5. 2-Hydroxypyridine-N-oxides: effective new chelators in iron mobilisation. Kontoghiorghes GJ Biochim Biophys Acta; 1987 Apr; 924(1):13-8. PubMed ID: 3828392 [TBL] [Abstract][Full Text] [Related]
6. PCTH: a novel orally active chelator for the treatment of iron overload disease. Lovejoy DB; Kalinowski D; Bernhardt PV; Richardson DR Hemoglobin; 2006; 30(1):93-104. PubMed ID: 16540421 [TBL] [Abstract][Full Text] [Related]
7. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Becker EM; Lovejoy DB; Greer JM; Watts R; Richardson DR Br J Pharmacol; 2003 Mar; 138(5):819-30. PubMed ID: 12642383 [TBL] [Abstract][Full Text] [Related]
8. Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311. Chaston TB; Lovejoy DB; Watts RN; Richardson DR Clin Cancer Res; 2003 Jan; 9(1):402-14. PubMed ID: 12538494 [TBL] [Abstract][Full Text] [Related]
9. Multidentate terephthalamidate and hydroxypyridonate ligands: towards new orally active chelators. Abergel RJ; Raymond KN Hemoglobin; 2011; 35(3):276-90. PubMed ID: 21599440 [TBL] [Abstract][Full Text] [Related]
10. Protection against hydrogen peroxide-mediated cytotoxicity in Friedreich's ataxia fibroblasts using novel iron chelators of the 2-pyridylcarboxaldehyde isonicotinoyl hydrazone class. Lim CK; Kalinowski DS; Richardson DR Mol Pharmacol; 2008 Jul; 74(1):225-35. PubMed ID: 18424550 [TBL] [Abstract][Full Text] [Related]
11. Wnt inhibitor screen reveals iron dependence of β-catenin signaling in cancers. Song S; Christova T; Perusini S; Alizadeh S; Bao RY; Miller BW; Hurren R; Jitkova Y; Gronda M; Isaac M; Joseph B; Subramaniam R; Aman A; Chau A; Hogge DE; Weir SJ; Kasper J; Schimmer AD; Al-awar R; Wrana JL; Attisano L Cancer Res; 2011 Dec; 71(24):7628-39. PubMed ID: 22009536 [TBL] [Abstract][Full Text] [Related]
12. Structure-Activity Relationships of Nitro-Substituted Aroylhydrazone Iron Chelators with Antioxidant and Antiproliferative Activities. Hrušková K; Potůčková E; Opálka L; Hergeselová T; Hašková P; Kovaříková P; Šimůnek T; Vávrová K Chem Res Toxicol; 2018 Jun; 31(6):435-446. PubMed ID: 29766723 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of the thiosemicarbazone, dithiocarbazonate, and 2'-pyrazinylhydrazone of pyrazinecarboxaldehyde as agents for the treatment of iron overload. Spingarn NE; Sartorelli AC J Med Chem; 1979 Nov; 22(11):1314-6. PubMed ID: 533878 [TBL] [Abstract][Full Text] [Related]
16. [The effects of various ligands on resorption, distribution and excretion of iron after oral administration]. Forth W; Pfleger K; Rummel W; Seifen E; Richmond SI Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1965 Dec; 252(3):242-57. PubMed ID: 4286718 [No Abstract] [Full Text] [Related]
17. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Yu Y; Wong J; Lovejoy DB; Kalinowski DS; Richardson DR Clin Cancer Res; 2006 Dec; 12(23):6876-83. PubMed ID: 17145804 [TBL] [Abstract][Full Text] [Related]
18. New orally active iron chelators. Kontoghiorghes GJ Lancet; 1985 Apr; 1(8432):817. PubMed ID: 2858689 [No Abstract] [Full Text] [Related]
19. Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series. Kalinowski DS; Sharpe PC; Bernhardt PV; Richardson DR J Med Chem; 2008 Jan; 51(2):331-44. PubMed ID: 18159922 [TBL] [Abstract][Full Text] [Related]
20. Orally active alpha-ketohydroxypyridine iron chelators: studies in mice. Kontoghiorghes GJ Mol Pharmacol; 1986 Dec; 30(6):670-3. PubMed ID: 3785144 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]